Caution: TIGIT + PD-(L)1 blockade
Adding a TIGIT blocker to PD-1/PD-L1 blockade looked good in phase 2 and then failed repeatedly in phase 3.
SKYSCRAPER-01 (tiragolumab + atezolizumab, NSCLC), SKYSCRAPER-02 (SCLC), and others negative; Roche and others discontinued most programmes in 2024-25. Phase 2 signals did not reproduce.
Pages like this
not linked directly; found by shared links- TargetTIM-3
Shares TIGIT, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- PersonTasuku Honjo
Shares PD-L1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- IdeaRandomised trials of stopping immunotherapy after one year versus continuing
Shares PD-L1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- ProductCosibelimab
Shares PD-L1, Immune checkpoint inhibitors.
- IdeaExtended-interval immunotherapy: give checkpoint inhibitors every 8-12 weeks once stable
Shares PD-L1, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- ProductEpacadostat
Shares No accelerated approval for a combination without proof each part contributes, Immune checkpoint inhibitors.
- InstitutionShandong Cancer Hospital and Institute
Shares Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
- InstitutionShanghai Pulmonary Hospital
Shares Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.